Symposia: Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Biological therapies, non-Hodgkin lymphoma, Lymphomas, Non-Biological therapies, Bispecific Antibody Therapy, Clinical Research, B Cell lymphoma, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Combination therapy, Diseases, indolent lymphoma, Therapies, Immunotherapy, aggressive lymphoma, Lymphoid Malignancies, Adverse Events, Monoclonal Antibody Therapy, Minimal Residual Disease
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Biological therapies, non-Hodgkin lymphoma, Lymphomas, Non-Biological therapies, Bispecific Antibody Therapy, Clinical Research, B Cell lymphoma, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Combination therapy, Diseases, indolent lymphoma, Therapies, Immunotherapy, aggressive lymphoma, Lymphoid Malignancies, Adverse Events, Monoclonal Antibody Therapy, Minimal Residual Disease
Saturday, December 10, 2022: 9:30 AM-11:00 AM
La Nouvelle Orleans Ballroom C
(Ernest N. Morial Convention Center)
Moderators:
Brad S. Kahl, MD, Washington University School of Medicine in St. Louis
and
Martin Dreyling, MD, University Hospital, LMU Munich
Disclosures:
Kahl: Janssen: Consultancy; Kite: Consultancy; Beigene: Consultancy, Research Funding; Celgene/BMS: Consultancy, Research Funding; Pharmacyclics: Consultancy; AcertaPharma: Consultancy; MEI: Consultancy; Abbvie: Consultancy, Research Funding; Genentech: Consultancy, Research Funding; Roche: Consultancy; ADT Therapeutics: Consultancy; AstraZeneca: Consultancy, Research Funding; Incyte: Consultancy; Hutchmed: Consultancy, Research Funding; TG Therapeutics: Consultancy; Genmab: Consultancy; Seattle Genetics: Consultancy; Research To Practice: Speakers Bureau. Dreyling: Lilly/Loxo: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria; Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Gilead/Kite: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS/Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Bayer: Research Funding; Abbvie: Research Funding; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Beigene: Consultancy.
This session predominantly focuses on the interventional studies in the mantle cell lymphoma
9:30 AM
9:45 AM
10:00 AM
10:15 AM
10:30 AM
10:45 AM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH